...focused on collagenase-based therapies, hired Kevin Buchi as CEO. Buchi was president and CEO of TetraLogic Pharmaceuticals Corp....

...Therapeutics Inc., Syros Pharmaceuticals Inc., Tensha Therapeutics Inc. -- now part of Roche -- and TetraLogic Pharmaceuticals Corp....

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp....

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp. Alicia...

...most recently CSO of Akriveia Therapeutics LLC (Thousand Oaks, Calif.), and was previously CSO at TetraLogic Pharmaceuticals Corp....
...to bridge the gap and consolidate the region's biotech investment expertise. Mark Zipkin Akriveia Therapeutics LLC Amgen Inc. Monash University TetraLogic Pharmaceuticals Corp. University...

...remetinostat dose. Last year, Medivir acquired remetinostat from TetraLogic Pharmaceuticals Corp. (see BioCentury, Nov. 3, 2016 ). TetraLogic...

...formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp....

...Akriveia Therapeutics LLC (Thousand Oaks, Calif.) named C. Glenn Begley CSO. He was CSO at TetraLogic Pharmaceuticals Corp....

...cash; TetraLogic will subsequently delist from NASDAQ and terminate all remaining employees by Dec. 1. TetraLogic...
...in regulatory milestones and $31 million in commercialization milestones, plus tiered royalties capped at 13%. TetraLogic...
...close this year, contingent on the approval of TetraLogic’s shareholders (see BioCentury, Feb. 1 ). TetraLogic Pharmaceuticals Corp....